Citigroup
MAZE

Citigroup’s Maze Therapeutics MAZE Stock Holding History

Citigroup’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903K Buy
30,265
+21,702
+253% +$569K ﹤0.01% 3525
2026
Q1 		$256K Sell
8,563
-2,689
-24% -$119K ﹤0.01% 3887
2025
Q4 		$466K Buy
11,252
+10,983
+4,083% +$377K ﹤0.01% 3609
2025
Q3 		$6.98K Sell
269
-12,721
-98% -$215K ﹤0.01% 5123
2025
Q2 		$159K Buy
12,990
+6,774
+109% +$70.5K ﹤0.01% 4166
2025
Q1 		$68.4K Buy
+6,216
New +$74.8K ﹤0.01% 4783

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Citigroup's MAZE Position: Q2 2026 in Review

Citigroup increased its Maze Therapeutics (MAZE) stake by 253% in Q2 2026, buying an estimated $569K and bringing the position to 30,265 shares worth $903K. The position accounts for ﹤0.01% of the portfolio, ranked #3525.

Citigroup first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Citigroup held 30,265 shares of Maze Therapeutics worth $903K as of Q2 2026.
  • Citigroup bought 21,702 Maze Therapeutics shares in Q2 2026, an estimated $569K.
  • Maze Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3525 holding.
  • Citigroup first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.